May 27, 2021 / 04:00AM GMT
Christian Hogg - HUTCHMED(China)Limited-CEO&Executive Director
Good morning or good afternoon, everybody. Welcome to the HUTCHMED R&D Commercial and ASCO Update follow-up call. As many of you know last night, Hong Kong time, we had a 2.5-hour event in which the team went through a 150-odd pages of updates on our pipeline, our commercial platform, our manufacturing efforts.
It was tailored primarily to -- because it was so late Hong Kong time, it was tailored primarily to U.K. and U.S. investors and analysts. So today, we are having a follow-up Q&A session so that Asia-based analysts or investors are able to pose their questions to the company.
If you could move on to Slide #3. This was the schedule of events or the agenda yesterday where we -- Dr. Wei-Guo Su and Dr. Marek Kania, took us through our development pipeline and our early discovery activities. Chen Hong and Tom Held took us through the commercial activities in China and the U.S. And then Dr. Zhenping Wu took us through our manufacturing strategy.
HUTCHMED (China) Ltd Corporate Call Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers